Supplementary Materials

Supplementary Material for:

Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration

Brian L. Yaspan, David F. Williams, Frank G. Holz, Carl D. Regillo, Zhengrong Li, Amy Dressen, Menno van Lookeren Campagne, Kha N. Le, Robert R. Graham, Tatiana Beres, Tushar R. Bhangale, Lee A. Honigberg, Ashley Smith, Erin C. Henry, Carole Ho, Erich C. Strauss;* for the MAHALO Study Investigators

*Corresponding author. Email: strauss.erich{at}gene.com

Published 21 June 2017, Sci. Transl. Med. 9, eaaf1443 (2017)
DOI: 10.1126/scitranslmed.aaf1443

This PDF file includes:

  • Fig. S1. Kaplan-Meier plot of time to study discontinuation by treatment group.
  • Fig. S2. Geographic atrophy progression with monthly and every other month lampalizumab treatment.
  • Fig. S3. Average CFI serum concentrations by rs17440077 genotype.
  • Fig. S4. Average CFI serum concentrations by rs4698775 genotype.
  • Table S1. Mean change in geographic atrophy area from baseline to month 18 by fundus autofluorescence and color fundus photography based on the mITT
    population (LOCF method).
  • Table S2. Least-squares mean change in best-corrected visual acuity from baseline based on the mITT population using LOCF data.
  • Table S3. SNP genotype counts and allele frequencies for patients assayed in the MAHALO study.
  • Table S4. Least-squares mean change in geographic atrophy area from baseline to month 18 by risk-allele status.
  • Table S5. Least-squares mean change in geographic atrophy area (mm2) by fundus autofluorescence from baseline by CFI status (rs17440077) based on the
    mITT population (observed data).
  • Table S6. Geographic atrophy progression by fundus autofluorescence in CFI+ subgroups (rs17440077) with monthly and every other month lampalizumab treatment versus sham control and baseline best-corrected visual acuity of 20/50 to 20/100 (Snellen equivalent).
  • Table S7. Least-squares mean change in geographic atrophy area (mm2) from baseline to month 18 by gender: CFI risk-allele carriers in mITT patients.
  • Table S8. Least-squares mean change in geographic atrophy area (mm2) by fundus autofluorescence from baseline by CFI status (rs4698775) based on the mITT population (observed data).
  • Table S9. Ocular adverse events in the fellow eye during the 18-month treatment period occurring among ≥3 patients in any treatment group (safety-valuable patients).
  • Table S10. Systemic (nonocular) adverse events during the 18-month treatment period occurring among ≥3 patients in any treatment group (safety-evaluable patients).
  • Table S11. Adverse events suspected to be caused by study drug during the 18-month treatment period (safety-evaluable patients).
  • Table S12. Serum and aqueous exposures in lampalizumab-treated patients.
  • Table S13. Summary of estimated accumulation ratios in lampalizumab-treated patients.
  • Table S14. CFI SNPs and relationships.
  • Table S15. Predicted mean change in geographic atrophy area from baseline: mITT patients.
  • Table S16. Predicted mean change in geographic atrophy area from baseline by CFI status: mITT patients.
  • Table S17. Least-squares mean change in geographic atrophy area from baseline to month 18 (study eye): mITT patients.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: